Sigma Systems Accelerates Product and Service Innovation for Hong Kong’s SmarTone
4.11.2019 06:00:00 EET | Business Wire | Press release
Sigma Systems, the global leader in catalog-driven software, today announces that it has been selected by SmarTone, a leading telecommunications provider with operating subsidiaries in Hong Kong and Macau, to accelerate its digital transformation and time-to-market for new products and offerings for its two million-plus customers.
Under this multi-year agreement, Sigma Systems will deploy Sigma Catalog, Sigma CPQ, Sigma Order Management, Sigma Portfolio Inventory and Sigma Insights, which constitute its award-winning Create-Sell-Deliver Portfolio. This will accelerate product and service innovation for SmarTone, expedite service delivery to customers and play a central role in supporting the service provider’s 5G-focused strategy. The implementation will be carried out in partnership with Hong Kong-headquartered WiseSpot, a leading systems integrator and solutions developer for the telecommunications industry.
Stephen Chau, Chief Technology Officer, SmarTone, commented: “Service excellence has always been our forte in setting us apart from our competition. At SmarTone, we strive to provide customers with an optimal user experience by continuously investing to improve our dynamic blend of key technologies and fine skills. With the advent of 5G, enhancing our core capability to more rapidly innovate around services will be vital in introducing new applications on IoT, mobile connectivity, edge computing and highly immersive, interactive experiences. By partnering with Sigma Systems, we will be better equipped to continue building our strength and serve our customers as their preferred service provider, as we look to roll out a new range products and services in line with our vision for a 5G future.”
Tim Spencer, Chief Executive Officer, Sigma Systems, commented: “In the age of digital services and 5G, driving product innovation and capitalizing upon new revenues is an imperative for CSPs. Today’s service providers need to create, sell and deliver services in a frictionless, automated and error-free way. At Sigma Systems, our strength lies in helping service providers successfully navigate complexities inherent in the current landscape and transform their businesses to accelerate product innovation – and get Next Done NowTM. This agreement with SmarTone is testament to the value that Sigma Systems’ Create-Sell-Deliver portfolio brings to any service provider and we are confident that with our unique offering, they will be able to launch new products and services seamlessly, and thus cater effectively to a new generation of consumers.”
For further information about Sigma Systems, its award-winning Create-Sell-Deliver portfolio, and getting Next Done NowTM visit sigma-systems.com, or contact us on info@sigma-systems.com.
About Sigma Systems (Twitter @SigmaSystems)
Sigma Systems is the global leader in catalog-driven software solutions for telecommunications, media and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and the Asia Pacific region, with technology and integration partners around the globe. Sigma is a Hansen Technologies company publicly listed on the Australian Stock Exchange – ASX:HSN.
Additional information can be found online at https://sigma-systems.com/.
Visit Hansen Technologies at https://www.hansencx.com/.
About SmarTone
SmarTone Telecommunications Holdings Limited (0315.HK) is a leading telecommunications company with operating subsidiaries in Hong Kong and Macau, providing voice, multimedia and mobile broadband services, as well as fixed fibre broadband services for the consumer and corporate markets. Its goal is to deliver unbeatable and valuable experiences to customers through its powerful network, purposeful apps and passionate service. The company has been listed in Hong Kong since 1996. It is a subsidiary of Sun Hung Kai Properties Limited (0016.HK).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191103005007/en/
Contact information
Adnan Bashir
Senior Corporate Communications Manager
Sigma Systems
+1 647-204-0999
Chloe Purcell
Head of PR
Milner Strategic Marketing Ltd.
+44 1473 633123
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom